For Research Use Only. Not for use in diagnostic procedures.
Purified human complement component C8. Complement component C8 is unique to the terminal complement pathway. It is composed of three protein chains (α 65 kD; ? 65 kD; Γ 22 kD) and is present in plasma at approximately 55 mg/L. Together with the other proteins of the terminal pathway, C8 forms the membrane attack complex or MAC.
All Quidel complement components are tested for functional activity in a standard lytic or applicable functional assay and for biochemical purity by SDS-polyacrylamide gel electrophoresis. Please refer to the Certificate of Analysis for lot specific information on functional titer.
Quidel's purified human complement components are useful in a wide variety of immunochemical and research applications. For assistance with a specific protocol, please contact Quidel Technical Support.
References
Nicholson-Weller, Butko, P, Wessels, M. Role of Complement Component C1q in IgG independent Opsonophagocytosis of Group B Streptococus, J. Immunol 163:2761-2768, 1999.
Koski, C., Dashell, S. Sublytic terminal complement complex decreases Po gene expression in schwan cells, J Neurochem 73(6):2321-2330, 1999.
Liu, C., et al. Interaction between the terminal complement pathway complex C5b-7 and anionic phospholipids, Blood 93(7)2291-2301, 1999.
Features & Benefits
| Feature | Benefit |
|---|
Product Specifications
| Product Spec Name | Product Spec Data |
|---|---|
|
Concentration
|
1.0 mg/mL |
|
Volume/vial
|
250 μL/vial |
|
Storage
|
At or below –70°C |
|
Purity
|
> 85% |
|
Buffer
|
PBS |
Ordering Information
| Catalog Number | Kit Size / Case Size |
|---|---|
|
A406
|
250 μL/vial
|
